These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23198660)

  • 1. Denosumab is an option for treatment of osteoporosis.
    Simonelli C
    Am Fam Physician; 2012 Dec; 86(11):992; author reply 994. PubMed ID: 23198660
    [No Abstract]   [Full Text] [Related]  

  • 2. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab in postmenopausal women with low bone mineral density.
    Schwartzman J; Yazici Y
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Denosumab for postmenopausal osteoporosis?
    Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab (prolia) for postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2010 Oct; 52(1349):81-2. PubMed ID: 21045756
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis.
    von Keyserlingk C; Hopkins R; Anastasilakis A; Toulis K; Goeree R; Tarride JE; Xie F
    Semin Arthritis Rheum; 2011 Oct; 41(2):178-86. PubMed ID: 21616520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab in postmenopausal women with low bone mineral density.
    Rifkin WD
    N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
    [No Abstract]   [Full Text] [Related]  

  • 10. Denosumab: an antifracture therapy for postmenopausal women with osteoporosis.
    Jiang X; Schnatz PF
    Menopause; 2013 Feb; 20(2):117-9. PubMed ID: 23299707
    [No Abstract]   [Full Text] [Related]  

  • 11. Denosumab (Prolia): A new option in the treatment of osteoporosis.
    Belavic JM
    Nurse Pract; 2011 Jan; 36(1):11-2. PubMed ID: 21173630
    [No Abstract]   [Full Text] [Related]  

  • 12. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
    Johnson GL
    Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
    [No Abstract]   [Full Text] [Related]  

  • 14. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To treat osteoporosis, Denosumab appears more effective than Zoledronate. Denosumab has the advantage in building bone density, and has fewer side effects.
    Duke Med Health News; 2014 Mar; 20(3):1-2. PubMed ID: 24683617
    [No Abstract]   [Full Text] [Related]  

  • 16. Atypical femoral fractures bilaterally in a patient receiving denosumab.
    Drampalos E; Skarpas G; Barbounakis N; Michos I
    Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it time to combine osteoporosis therapies?
    Eastell R; Walsh JS
    Lancet; 2013 Jul; 382(9886):5-7. PubMed ID: 23683601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.